Liquid biopsy was not always an option for molecular laboratories due to the short 4-hour window from blood collection to cfDNA extraction, time intensive workflows, and the need for specific technical expertise.
From sample collection, polymerase chain reaction (PCR) testing, and next-generation sequencing (NGS)—Roche’s robust liquid biopsy portfolio is bringing new possibilities to clinical research and diagnostics.
From simple PCR workflows to the turnkey NGS kit-based solution, the Roche Liquid Biopsy portfolio facilitates in-house adoption of liquid biopsy testing.
Download this scientific summary on how comprehensive genomic profiling of liquid biopsies could facilitate personalised healthcare in oncology.
As the intricacies of cancer become better understood, new discoveries will follow.
From uncovering the next major breakthrough to monitoring for disease progression, the Roche liquid biopsy portfolio can help make your vision of personalized patient care a reality.
Download a scientific summary on liquid biopsy
BRAF/NRAS Mutation Test (LSR)
Qualitative detection and identification of mutations in the BRAF gene and the NRAS viral oncogenes.
KRAS Mutation Test v2 (LSR)
Qualitative detection and identification of 28 mutations in exons 2, 3, and 4 of the KRAS gene.
cobas® EGFR Mutation Test v2
A companion diagnostic test to identify 42 mutations in the EGFR gene, including the T790M resistance mutation.
AVENIO ctDNA Analysis Kits (RUO)
A portfolio of assay kits – all set and ready for you to use for tumor profiling and surveillance & monitoring.
AVENIO ctDNA Analysis Kits, Roche/AVENIO NGS liquid biopsy assays, BRAF/NRAS Mutation Test, KRAS Mutation Test v2, and the RUO version of the Roche Cell-Free DNA Collection Tube are For Research Use Only, and not for use in diagnostic procedures.
RUO: Research Use Only
LSR: Life Science Research
